Overview
Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma
Status:
Completed
Completed
Trial end date:
2013-07-01
2013-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to test hypothesis if Sereflo (ICS/LABA) could reduce airway inflammation in asthmatic patients in the same as Seretide.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mahidol UniversityTreatments:
Anti-Inflammatory Agents
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Fluticasone-Salmeterol Drug Combination
Criteria
Inclusion Criteria:- Age between 20-80 years
- Patients with asthma diagnosed by according to the American Thoracic Society criteria
- A baseline FEV1 > or = 50% predicted with a reversibility of FEV1 after therapy with
inhaled salbuterol (2.5 mg) of FEV1 12% or with provocative concentration of a
methacholine causing a 20% fall in FEV1 (PC20) of < or = 8 mg/mL
- Prescribed use of inhaled corticosteroids (any brand) for at least 12 weeks prior to
study entry
- The daily prescribed dose of inhaled corticosteroids during the last 4 weeks prior to
study entry should have been constant and at least 250 μg/day of fluticasone at least
400 μg/day of budesonide at least 500 μg/day of any other beclomethasone
- Be able to provide written informed consent
Exclusion Criteria:
- Any asthma exacerbation or respiratory tract infection affecting asthma within 4 weeks
prior to the randomization visit
- Intake of oral, parenteral corticosteroids within 4 weeks and/or depot parenteral
corticosteroid within 12 weeks prior to the randomization visits
- Current or previous smoker with a smoking history of > or = 10 pack years
- Previous randomization of treatment in the present study
- Known or suspected hypersensitivity to study therapy
- Use of any β-blocking agent, including eye-drops
- Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not
using acceptable contraceptive pill measures